Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Endoscopic laser ablation plus Enfortumab vedotin and Toripalimab for localized high-risk UTUC (Phase II)
ChiCTR2600121637Phase 2Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Apr 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of enfortumab vedotin and toripalimab in upper tract urothelial carcinoma (UTUC), sponsored by West China Hospital of Sichuan University. Primary endpoint: Conversion-free survival. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
enfortumab vedotintoripalimab
03
Conditions
upper tract urothelial carcinoma (UTUC)
Beyond the preview
Go deeper on ChiCTR2600121637.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600121637.